References
Srinivas NR. Comment on: “Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer”. Clin Pharmacokinet. 2016;. doi:10.1007/s40262-016-0468-2.
Xu XS, Ryan CJ, Stuyckens K, et al. Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2016. [Epub ahead of print].
Stuyckens K, Saad F, Xu XS, et al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014;53:1149–60.
Attard G, Reid AHM, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563–71.
Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481–8.
Reid AHM, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28:1489–95.
Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28:1496–501.
Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92.
Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.
Carles J, Davis ID, de Bono JS, et al. Safety of long-term treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer patients with abiraterone acetate plus prednisone for ≥4 years. Poster presented at the European Society of Medical Oncology 2016 Congress, 7–11 October 2016, Copenhagen, Denmark. Abstr No 740P
Emamekhoo H, Li Z, Sharifi N. Clinical significance of D4A in prostate cancer therapy with abiraterone. Cell Cycle. 2015;14:3213–4.
Li Z, Bishop A, Alyamani M, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523:347–51.
Acknowledgements
Funding was provided by Janssen Research & Development. Writing assistance was provided by Shala Thomas, PhD, of PAREXEL and was funded by Janssen Global Services, LLC.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
XS Xu and P De Porre are employees of Janssen Research & Development and own stock in Johnson & Johnson.
Additional information
This is a reply to the letter available at doi:10.1007/s40262-016-0468-2.
This is a reply to the letter of the original article available at doi:10.1007/s40262-016-0425-0.
Rights and permissions
About this article
Cite this article
Xu, S., De Porre, P. Author’s Reply to Srinivas: “Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer”. Clin Pharmacokinet 56, 213–214 (2017). https://doi.org/10.1007/s40262-016-0469-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40262-016-0469-1